A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

Hematologic Malignancies Clinical Trial

Official title:

An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability，Pharmacokinetic/Pharmacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-035 in Participants With Relapsed/Refractory Hematologic Malignancy and Locally Advanced or Metastatic Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05104775
• Other study ID #: GNC-035-101
• Status: Recruiting
• Phase: Phase 1
• Start date: February 9, 2022
• Est. completion date: December 2024

Study information

• Verified date: March 2024
• Source: Sichuan Baili Pharmaceutical Co., Ltd.
• Contact: Hai Zhu
• Phone: +86-13980051002
• Email: zhuhai[@]baili-pharm.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, the safety, tolerability and preliminary effectiveness of GNC-035 in patients with relapsed/refractory hematologic malignancies will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-035.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 58
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. The participants could understand and sign the informed consent form, and must participate voluntarily

2. No gender limit

3. Age: =18 and =75 years old

4. Life expectancy estimated to be at least 3 months

5. Histologically or cytologically confirmed relapsed or refractory non-Hodgkin's lymphoma, relapsed/refractory chronic lymphocytic leukemia, relapsed/refractory acute B-lymphoblastic leukemia, or relapsed/refractory acute myeloid leukemia

6. For relapsed or refractory chronic lymphocytic leukemia (CLL/SLL), specifically:

• Patients who have relapsed after at least 1 line of standard therapy or who have failed or are intolerant to standard therapy;
• Patients with relapsed or refractory chronic lymphocytic leukemia who, in the opinion of the investigator, have none or are not suitable/intolerant to other therapies;

7. For other patients with relapsed and refractory non-Hodgkin's lymphoma. These include:

• Patients in first relapse who still progress during second-line treatment;
• Patients who relapsed after second-line or multi-line therapy;
• Refractory patients are defined as those who do not respond or progress after adequate dose and full cycle of standard or current commonly selected combination therapy regimens, and do not respond or progress after replacement of second-line regimens;
• Relapsed or refractory patients who are judged by the investigator to have no or no indication/intolerance to other therapy.

8. Relapsed or refractory acute B-lymphoblastic leukemia, including:

• Definition of refractory ALL: failure to achieve CR after standard induction therapy for bone marrow and peripheral blood response;
• Relapsed ALL is defined as the presence of blasts (> 5%) in the peripheral blood or bone marrow, or the presence of extramedullary disease in patients who have achieved CR; mediastinal enlargement in patients who have achieved CR.
• Special circumstances: There is no clear classification standard for adult ALL patients with number of relapse = 2, persistent extramedullary leukemia and persistent positive minimal residual disease (MRD). However, most clinical trials classified these patients as refractory cases.
• Patients with relapsed or refractory acute B-lymphoblastic leukemia who, in the opinion of the investigator, have no or no indication/intolerance to other therapy.

9. Relapsed/refractory acute myeloid leukemia (AML), relapsed/refractory AML is defined

as one of the following:

• Initial treatment who failed to respond to 2 courses of standard regimen;
• Patients with relapse within 12 months , consolidation and intensive treatment after complete remission;
• Patients who relapsed after 12 months but failed to respond to conventional chemotherapy;
• Patients with two or more recurrences;
• Patients with persistent extramedullary leukemia;
• Patients with relapsed or refractory acute myeloid leukemia who have no or no indication/intolerance to other therapy as judged by the investigator.

10. Patients with Philadelphia chromosome positive (Ph +) acute lymphoblastic leukemia are eligible if they are intolerant or have failed first and/or second generation tyrosine kinase inhibitors (TKIs); patients with a positive T315I mutation do not require TKI salvage

11. For non-Hodgkin lymphoma, measurable lesions on CT (any lymph node lesion = 1.5 cm in long diameter or > 1.0 cm in long diameter for extranodal lesions) at screening; CLL/SLL: peripheral blood leukemia cells = 5.0 × 109/L; or any lymph node lesion = 1.5 cm in long diameter; WM: IgM 2 × ULN;

12. For patients with acute lymphoblastic leukemia, = 5% lymphoblasts in the bone marrow by morphologic assessment

13. For patients with acute myeloid leukemia, = 5% blasts in the bone marrow by morphologic assessment

14. ECOG Performance Status = 2

15. Recovery from toxicities of prior anticancer therapy to = Grade 1 as defined by NCI-CTCAEv5.0 (except alopecia)

16. The organ function level within 7 days before the first administration meets the following requirements: Bone marrow function (only for patients with non-Hodgkin's lymphoma): Neutrophils without blood transfusion, G-CSF (without long-acting whitening needles within 2 weeks) and drug correction within 7 days before screening Absolute count (ANC) =1.0×10^9/L (for subjects with bone marrow infiltration, =0.5×10^9/L); hemoglobin =80 g/L (for subjects with bone marrow infiltration, =70g /L); Platelet count =50×10^9/L; Liver function: In the case of no hepatoprotective drugs for correction within 7 days before screening, total bilirubin = 1.5 ULN (Gilbert's syndrome = 3 ULN), transaminase (AST/ALT) = 2.5 ULN (tumor invasive changes in the liver) Subject =5.0 ULN), and/or alkaline phosphatase =5 ULN; Kidney function: creatinine (Cr) = 1.5 ULN or creatinine clearance (Ccr) = 50 mL/min (calculated by the research center); Coagulation function: fibrinogen = 1.5g/L; activated partial thromboplastin time (APTT) = 1.5 × ULN; prothrombin time (PT) = 1.5 × ULN;

17. Female participants with fertility or male participants whose partner(s) are fertile must take effective contraceptive measures from 7 days prior to the first administration to 12 weeks after the administration. Female participants with fertility must have a negative serum/urine pregnancy test in 7 days prior to the first dose.

18. Subjects are capable and willing to comply with the visits, treatment plans, laboratory examinations and other research-related procedures stipulated in the research protocol.

Exclusion Criteria:

1. Patients who have undergone major surgery within 28 days prior to dosing in this study, or are scheduled to undergo major surgery during this study ("major surgery"is defined by the investigator)

2. Pulmonary disease = grade 3 according to NCI-CTCAEv5.0: including resting dyspnea, or requiring continuous oxygen therapy; patients with current interstitial lung disease (ILD) (except for those with previous interstitial pneumonia)

3. Systemic serious infections occurred within 4 weeks before screening,including but not limited to severe pneumonia, bacteremia or serious infectious complications caused by fungi, bacteria and viruses

4. Patients with active autoimmune diseases, or patients with a history of autoimmune diseases

5. Patients complicated with other malignant tumors within 5 years before the first dose, and cured non-melanoma in situ skin cancer, superficial bladder cancer, in situ cervical cancer, gastrointestinal intramucosal cancer, breast cancer, localized prostate cancer and other cancers that are considered by the investigator to be eligible

6. Positive human immunodeficiency virus antibody (HIVAb), active tuberculosis, active hepatitis B virus infection (positive HBsAg or positive HBcAb with HBV-DNA = ULN), or hepatitis C virus infection (positive HCV antibody with HCV-RNA = ULN)

7. Hypertension poorly controlled on medication (systolic > 150 mmHg or diastolic > 100 mmHg)

8. Left ventricular ejection fraction = 45%, or history of significant cardiac disease within 1 year

9. Patients with a history of hypersensitivity to recombinant humanized antibodies or hypersensitivity to any of the excipient components of GNC-035

10. Women who are pregnant or breastfeeding

11. Previous or concomitant central nervous system disease

12. With CNS involvement

13. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (ALLo-HSCT)

14. Autologous hematopoietic stem cell transplantation (Auto-HSCT) was performed 12 weeks before starting GNC-035 treatment

15. Are using immunosuppressive agents, including but not limited to: Cyclosporine, tacrolimus, etc. within 2 weeks before GNC-035 treatment; High-dose glucocorticoids (longer than 14 days) within 2 weeks before GNC-035 treatment , A daily stable dose of >30mg of prednisone or the same dose of other glucocorticoids);

16. Radiotherapy 4 times before starting GNC-035 treatment; chemotherapy and small molecule targeted drugs 2 weeks before treatment

17. CD19 or anti-CD22 treatment and still respond, received Amgen Belintotumomab (CD19×CD3), inotuzumab-oxazomicin (CD22-ADC) treatment within 4 weeks before treatment;

18. Received CAR-T 12 weeks prior to starting GNC-035

19. Has receivedany other clinical trial within 4 weeks prior to GNC-035 treatment

20. The investigator believes that it is not suitable to participate in other situations in this clinical trial.

Related Conditions & MeSH terms

• Hematologic Malignancies
• Hematologic Neoplasms
• Neoplasms

Intervention

Drug:
• GNC-035
Administration by intravenous infusion.

Locations

Country	Name	City	State
China	Guangzhou First People's Hospital	Guangzhou	Guangdong
China	Affiliated Hospital of Guizhou Medical University	Guiyang	Guizhou
China	Ruijin Hospital, Shanghai Jiaotong University School of Medicine	Shanghai	Shanghai
China	Shengjing Hospital of China Medical University	Shenyang	Liaoning
China	The Fourth Hospital of Hebei Medical University	Shijiazhuang	Hebei
China	Union Hospital Tongji Medical College Huazhong University of Science and Technology	Wuhan	Hubei
China	The Second People's Hospital of Yibin	Yibin	Sichuang

Sponsors (2)

Lead Sponsor	Collaborator
Sichuan Baili Pharmaceutical Co., Ltd.	SystImmune Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	DLT	Dose limiting toxicity	Up to 2 weeks
Primary	MTD or MAD	Maximum tolerated dose or maximum administrated dose	Up to 2 weeks
Primary	TEAE	Treatment-Emergent Adverse Event	Up to 2 years
Primary	The recommended dose for future clinical study	The recommended dose for future clinical study	Up to 2 weeks
Primary	RP2D	Recommended phase II dose	Up to 2 years
Secondary	AESI	Adverse Events of special interest	Up to 2 years
Secondary	Cmax	Maximum serum concentration of GNC-035	Up to 2 weeks
Secondary	Tmax	Time to maximum serum concentration (Tmax) of GNC-035	Up to 2 weeks
Secondary	T1/2	Half-life of GNC-035	Up to 2 weeks
Secondary	Incidence and titer of ADA	Anti-drug antibody	Up to 2 years
Secondary	ORR	Objective Response Rate	Up to 2 years
Secondary	DCR	Disease Control Rate	Up to 2 years
Secondary	PFS	Progression-free Survival	Up to 2 years
Secondary	DOR	Duration of Response	Up to 2 years